A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients

Yutani, Shigeru; Komatsu, Nobukazu; Yoshitomi, Munehiro; Matsueda, Satoko; Yonemoto, Koji; Mizutani, Takashi; Noguchi, Masanori; Ishihara, Yuki; Yamada, Akira; Itoh, Kyogo; Sasada, Tetsuro

doi:10.3892/or.2013.2556

Cited by 45 publications

(37 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Particularly for cancer vaccines, it is crucial to identify appropriate biomarkers to predict overall survival, since only some patients will show clinical benefit. Our previous clinical studies of PPV indicated that several biomarkers were significantly correlated with the OS . In the case of NSCLC, a high CRP level at pre‐vaccination and a low frequency of CD26 + T‐cells in the peripheral blood after one vaccination cycle were significant biomarkers of unfavorable OS .…”

Section: Discussionmentioning

confidence: 99%

PD‐1 expression on peripheral blood T‐cell subsets correlates with prognosis in non‐small cell lung cancer

et al. 2014

Self Cite

View full text Add to dashboard Cite

PD-1 expression in peripheral blood T-cells has been reported in several kinds of cancers, including lung cancer. However, the relationship between PD-1 expression in peripheral blood T-cells and prognosis after treatment with a cancer vaccine has not been reported. To elucidate this relationship, we analyzed PD-1 expression in the peripheral blood T-cells of patients with non-small cell lung cancer. The blood samples used in this study were obtained from patients enrolled in phase II clinical trials of a personalized peptide vaccine. Seventy-eight samples obtained before and after a single vaccination cycle (consisting of six or eight doses) were subjected to the analysis. PD-1 was expressed on lymphocytes in the majority of samples. The relative contents of PD1+CD4+ T-cells against total lymphocytes before and after the vaccination cycle correlated with overall survival (OS) with a high degree of statistical significance (P < 0.0001 and P = 0.0014). A decrease in PD-1+CD8+ T-cells after one cycle of vaccination also correlated with longer OS (P = 0.032). The IgG response to the non-vaccinated peptides suggested that the epitope spreading seemed to occur more frequently in high-PD-1+CD4+ T-cell groups. Enrichment of CD45RA−CCR7− effector-memory phenotype cells in PD-1+ T-cells in PBMCs was also shown. These results suggest that PD-1 expression on the peripheral blood T-cell subsets can become a new prognostic marker in non-small cell lung cancer patients treated with personalized peptide vaccination.

show abstract

Section: Discussionmentioning

confidence: 99%

PD‐1 expression on peripheral blood T‐cell subsets correlates with prognosis in non‐small cell lung cancer

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…Yanagimoto et al . and Yutani et al . reported a phase II study of a personalized peptide vaccination for pancreatic cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Synergistic anti‐pancreatic cancer immunological effects by treatment with reduced expression in immortalized cells/dickkopf‐3 protein and peripheral blood mononuclear cells

Uchida

Shiraha

Kato

et al. 2016

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…In a previous study, a set of 31 peptides was used to create personalized vaccines for advanced PDAC [53]. A maximum of four peptides were selected from among the 31-peptide set based on the results of HLA typing and the patients' peptide-specific IgG titers.…”

Section: Multiple Vaccinesmentioning

confidence: 99%

Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?

et al. 2015

View full text Add to dashboard Cite

Pancreatic tumors are chemoresistant and malignant, and there are very few therapeutic options for pancreatic cancer, as the disease is normally diagnosed at an advanced stage. Although attempts have been made to develop vaccine therapies for pancreatic cancer for a couple of decades, none of the resultant protocols or regimens have succeeded in improving the clinical outcomes of patients. We herein review vaccines tested within the past few years, including peptide, biological and multiple vaccines, and describe the three sets of criteria used to evaluate the therapeutic activity of vaccines in solid tumors.

show abstract

A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients

Cited by 45 publications

References 15 publications

PD‐1 expression on peripheral blood T‐cell subsets correlates with prognosis in non‐small cell lung cancer

PD‐1 expression on peripheral blood T‐cell subsets correlates with prognosis in non‐small cell lung cancer

Synergistic anti‐pancreatic cancer immunological effects by treatment with reduced expression in immortalized cells/dickkopf‐3 protein and peripheral blood mononuclear cells

Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?

Contact Info

Product

Resources

About